middle.news
Can Biotron’s BIT-HBV001 Revolutionize Hepatitis B Treatment?
8:39am on Friday 14th of November, 2025 AEDT
•
Biotechnology
Read Story
Can Biotron’s BIT-HBV001 Revolutionize Hepatitis B Treatment?
8:39am on Friday 14th of November, 2025 AEDT
Key Points
BIT-HBV001 reduces HBV DNA by over 60% in two mouse models
Superior inhibition of multiple HBV replication markers compared to Tenofovir
Combination with Tenofovir shows synergistic antiviral effects
Patent application filed for BIT-HBV001 and related compounds
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE